Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 81.75% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $5.6 billion (up 50.24% YoY), while the FY2025 annual figure was $1.7 billion, up 78.2% from the prior year.
• Liabilities and Shareholders Equity retreated to $1.7 billion in Q1 2026 per KYMR's latest filing, from $1.7 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.7 billion in Q4 2025 and bottomed at $523.4 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $877.8 million across 5 years, with a median of $826.0 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity fell 13.48% — and 2024, when it surged 87.34%.
• Kymera Therapeutics' Liabilities and Shareholders Equity stood at $603.1 million in 2022, then slipped by 4.54% to $575.8 million in 2023, then jumped by 69.87% to $978.0 million in 2024, then jumped by 78.2% to $1.7 billion in 2025, then decreased by 4.23% to $1.7 billion in 2026.
• Business Quant data shows KYMR's Liabilities and Shareholders Equity at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.1 billion in Q3 2025.